NRx Pharmaceuticals, Inc.
NRXP
$3.87
-$0.46-10.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.65% | 306.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.65% | 306.20% | |||
| Cost of Revenue | 54.66% | 320.62% | |||
| Gross Profit | -24.00% | 296.55% | |||
| SG&A Expenses | -16.55% | 62.71% | |||
| Depreciation & Amortization | 50.00% | 61.54% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.29% | 27.91% | |||
| Operating Income | -3.35% | -11.56% | |||
| Income Before Tax | -497.22% | 106.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -497.22% | 106.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -497.22% | 106.11% | |||
| EBIT | -3.35% | -11.56% | |||
| EBITDA | -2.92% | -10.79% | |||
| EPS Basic | -456.45% | 104.68% | |||
| Normalized Basic EPS | 64.90% | 37.14% | |||
| EPS Diluted | -456.45% | 104.68% | |||
| Normalized Diluted EPS | 64.90% | 37.14% | |||
| Average Basic Shares Outstanding | 11.62% | 30.27% | |||
| Average Diluted Shares Outstanding | 11.62% | 30.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||